Literature DB >> 16485544

A case of hepatocellular carcinoma initially treated by carbon ions, followed by protons for marginal recurrence with portal thrombus.

Hiroshi Mayahara1, Yasue Oda, Atsuya Kawaguchi, Kazufumi Kagawa, Masao Murakami, Yoshio Hishikawa, Hiroshi Igaki, Koichi Tokuuye, Mitsuyuki Abe.   

Abstract

We report a case of hepatocellular carcinoma (HCC), initially treated by carbon ions, then subsequently by protons for marginal recurrence. A 52-year-old man with stage II HCC was enrolled in the clinical study for carbon ion therapy. A total dose of 52.5 GyE in 8 fractions was delivered through a right lateral port for 13 days. Dynamic CT performed 7 months after the initiation of carbon ion therapy showed a decrease in the size of the tumor. Dynamic CT performed 12 months after the therapy revealed marginal recurrence of HCC accompanied with portal vein tumor thrombus (PVTT). Proton therapy of 66 GyE in 22 fractions was delivered through posterior and right lateral ports for 33 days. Dynamic CT performed 3 months after the initiation of proton therapy showed a regression of the recurrent tumor and disappearance of the PVTT. No serious adverse effects were observed during or after these two treatments. He was free from further recurrence 27 months after the initiation of the first carbon ion therapy. Both carbon ions and protons were effective with minimal side effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16485544

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  2 in total

1.  A systematic review of publications on charged particle therapy for hepatocellular carcinoma.

Authors:  Hiroshi Igaki; Masashi Mizumoto; Toshiyuki Okumura; Kiyoshi Hasegawa; Norihiro Kokudo; Hideyuki Sakurai
Journal:  Int J Clin Oncol       Date:  2017-09-04       Impact factor: 3.402

2.  Low energy proton beam induces tumor cell apoptosis through reactive oxygen species and activation of caspases.

Authors:  Kheun Byeol Lee; Jong Soo Lee; Jeen Woo Park; Tae Lin Huh; You Mie Lee
Journal:  Exp Mol Med       Date:  2008-02-29       Impact factor: 8.718

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.